TRACON Pharmaceuticals is a biopharmaceutical company. Co. has a collaboration and clinical trial agreement for the development of envafolimab, an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma in North America. Other clinical stage oncology product candidates include: YH001, which is a monospecific investigational CTLA-4 antibody, that Co. licensed from Eucure (Beijing) Biopharma Co., Ltd. and Biocytogen Pharmaceuticals (Beijing) Co., Ltd., TRC102, which is a small molecule for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors, and TJ004309, which is a CD73 antibody for the treatment of solid tumors. The TCON stock yearly return is shown above.
The yearly return on the TCON stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TCON annual return calculation with any dividends reinvested as applicable (on ex-dates).
|